European Observational Study on Pasireotide LAR in Acromegaly – ACRONIS
CODE: CSOM230CIC05
Sponsor: Novartis Pharma Services AG
Study on the efficacy and safety of Afinitor® (everolimus) in patients with non-surgical or metastatic pancreatic neuroendocrine tumors G1 or G2, with progressive disease – PROTOR
CODE: CRAD001PGR07
Sponsor: Novartis Pharma Services AG
A double-blind, placebo-controlled, randomized withdrawal study after open-label therapy to evaluate the safety and efficacy of levocetoconazole (2S, 4R-ketoconazole) in the treatment of Endogenous Cushing’s Syndrome
CODE: COR-2017-01
Sponsor: Cortendo AB
ASPEN study: A Prospective Evaluation of the Management of Sporadic Asymptomatic Non-functioning Pancreatic Neuroendocrine Neoplasms ≤2
Evaluation of the effect of denosumab in adult patients with Langerhans cell histiocytosis (LCH): a multicenter, single-stranded, open-label clinical trial
CODE: 20159460
Adaptation of the existing EORTC QLQ-GINET21 module to develop a specific module for use in patients with Pancreatic Neuroendocrine Tumor, Phases I to III